Information Provided By: 
Fly News Breaks for August 28, 2017
TTPH
Aug 28, 2017 | 05:43 EDT
Piper Jaffray analyst Edward Tenthoff started Tetraphase Pharmaceuticals with an Overweight rating and $14 price target. The shares closed Friday up 10c to $6.51. Tetraphase, which is developing antibiotics to treat severe multi-drug resistant infections, recently reported positive Phase III data showing twice-daily intravenous eravacycline to be non-inferior to three-times daily meropenem in complicated intra-abdominal infections with a better safety profile, Tenthoff tells investors in a research note. He values eravacycline in cIAI at $378M.
News For TTPH From the Last 2 Days
There are no results for your query TTPH
